Cumberland Pharmaceuticals Inc. Q3 FY2025 earnings call

• Entered into arrangements with RedHill Biopharma to jointly commercialize Talicia, a treatment for helicobacter pylori infections. Formed Talicia Holdings, Inc. with RedHill, with Cumberland investing $2 million each in 2024 and 2025.
• Launched Vibativ in Saudi Arabia following an agreement with to book pharmaceutical manufacturing company. Regulatory approval of ibuprofen injection product in Mexico with PiSA Pharmaceutical. Antibiotic batter approved in China.
• Vibativ starter pack available through supply arrangement with Vizient and added to national purchasing agreement with Premier Inc.
• Updates on brands: Kristalose facing substitution by generic alternatives but strategies in place; Caldolor with new pediatric labeling and growing use in children's hospitals; Sancuso with favorable sales results and new website; Vaprisol's new manufacturing partner awaiting FDA GMP certification.
• Progress in ifetroban clinical programs: FIGHT DMD trial results, enrollment completed in systemic sclerosis study, and idiopathic pulmonary fibrosis trial underway.

For the third quarter of 2025, net revenue from continuing operations was $8.3 million. Net revenue by product for the third quarter included $1.2 million for Kristalose, $3.2 million for Sancuso, $2.6 million for Vibativ, and $0.9 million for Caldolor. Year-to-date, product revenues totaled $7.4 million for Kristalose, $8.6 million for Sancuso, $6.7 million for Vibativ, and $3.8 million for Caldolor.

• Expect continued momentum across approved brands.
• Anticipate increased international contributions.
• Look forward to further progress in clinical pipeline.
• Expect new opportunities for select product additions.

• Factors that could affect future results include natural disasters, economic downturns, international conflicts, trade restrictions, public health epidemics, and others beyond the company's control.